ATRA - Company ID 0001604464
The table below shows Atara Biotherapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $516.00K | $3.45M | $17.57M | $98.15M | $40.19M | $28.64M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $164.00K | $2.92M | $7.31M | $27.43M | $43.92M | $33.33M |
Atara Biotherapeutics, Inc. reported annual revenue of $120.77M for fiscal year 2025. That is down 6.3% from $128.94M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $3.60M |
| $3.99M |
| $6.51M |
| $11.47M |
| $10.42M |
| $8.91M |
| Operating income | -$3.37M | -$3.57M | $3.20M | $38.80M | -$21.76M | -$18.23M |
| Income tax | $0.00 | $28.00K | $3.00K | $0.00 | -$17.00K | $0.00 |
| Net income | -$4.14M | -$4.30M | $2.39M | $38.01M | -$21.91M | -$19.05M |
| EPS (diluted) | -$0.29 | -$0.32 | $0.19 | $3.50 | -$2.93 | -$3.10 |